JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Clearside Biomedical Inc

Closed

0.41 2.5

Overview

Share price change

24h

Current

Min

0.39

Max

0.42

Key metrics

By Trading Economics

Income

-917K

-8.2M

Sales

2M

2.3M

Profit margin

-352.918

Employees

32

EBITDA

-102K

-4.8M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+773.81% upside

Dividends

By Dow Jones

Next Earnings

11 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-34M

35M

Previous open

-2.09

Previous close

0.41

Technical Score

By Trading Central

Confidence

Neutral Evidence

Clearside Biomedical Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Aug 2025, 23:11 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 Aug 2025, 22:45 UTC

Earnings

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 Aug 2025, 22:39 UTC

Earnings

Great-West Lifeco Logs Lower 2Q Profit

5 Aug 2025, 21:32 UTC

Earnings

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 Aug 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 Aug 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 Aug 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 Aug 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 Aug 2025, 23:48 UTC

Market Talk

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 Aug 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 Aug 2025, 23:19 UTC

Market Talk

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 Aug 2025, 23:03 UTC

Market Talk
Earnings

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 Aug 2025, 22:22 UTC

Earnings

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 Aug 2025, 22:21 UTC

Earnings

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 Aug 2025, 22:20 UTC

Earnings

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 Aug 2025, 22:18 UTC

Earnings

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 Aug 2025, 22:17 UTC

Earnings

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 Aug 2025, 22:17 UTC

Earnings

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 Aug 2025, 22:16 UTC

Earnings

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 Aug 2025, 22:16 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 Aug 2025, 22:15 UTC

Earnings

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 Aug 2025, 22:13 UTC

Earnings

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 Aug 2025, 22:13 UTC

Earnings

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 Aug 2025, 22:12 UTC

Earnings

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 Aug 2025, 22:12 UTC

Earnings

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 Aug 2025, 21:58 UTC

Earnings

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 Aug 2025, 21:30 UTC

Earnings

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 Aug 2025, 21:26 UTC

Earnings

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 Aug 2025, 21:23 UTC

Earnings

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 Aug 2025, 21:17 UTC

Earnings

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Peer Comparison

Price change

Clearside Biomedical Inc Forecast

Price Target

By TipRanks

773.81% upside

12 Months Forecast

Average 3.67 USD  773.81%

High 6 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forClearside Biomedical Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

0

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

0.8417 / 0.8939Support & Resistance

Short Term

Neutral Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.